Here you can find corporate releases on topics related to governance, investments and important announcements.
CORMEDIX INC. SUPPORTS CMS POLICY UPDATES REGARDING ACCESS TO INNOVATIVE DRUG PRODUCTS
Read more
2024-11-26
CORMEDIX INC. TO PARTICIPATE IN THE TRUIST SECURITIES BIOPHARMA SYMPOSIUM
Read more
2024-11-04
CORMEDIX INC. REPORTS THIRD QUARTER AND NINE MONTH 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2024-10-30
CORMEDIX INC. ANNOUNCES NEW DATA AT ASN KIDNEY WEEK 2024
Read more
2024-10-24
CORMEDIX INC. TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON OCTOBER 30, 2024
Read more
2024-10-23
CorMedix Announces New Commercial Agreement with Mid-Sized Dialysis Operator
Read more
2024-10-08
CORMEDIX INC. ANNOUNCES NEW COMMERCIAL AGREEMENT
Read more
2024-09-19
CORMEDIX INC. TO PRESENT AT THE CANTOR GLOBAL HEALTHCARE CONFERENCE
Read more
2024-09-13
CORMEDIX INC. ANNOUNCES NEW COMMERCIAL AGREEMENT
Read more
2024-09-09
CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2024 Financial Results and Provides Business Update
Read more
2024-08-14
CORMEDIX INC. TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 14, 2024
Read more
2024-08-07
CORMEDIX INC. ANNOUNCES OUTPATIENT AVAILABILITY OF DEFENCATH
Read more
2024-07-03
CORMEDIX INC. RECEIVES FDA FEEDBACK ON POTENTIAL LABEL EXPANSION
Read more
2024-06-18
CORMEDIX INC. ANNOUNCES CMS GRANTS PASS-THROUGH STATUS TO DEFENCATH
Read more
2024-06-06
CORMEDIX INC. ANNOUNCES COMMERCIAL AGREEMENT WITH TOP TIER DIALYSIS PROVIDER
Read more
2024-05-28
CORMEDIX INC. TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES
Read more
2024-05-10
CORMEDIX INC. REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2024-05-09
CORMEDIX INC. TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 9, 2024
Read more
2024-05-06
CORMEDIX INC. ANNOUNCES CMS GRANTS TDAPA TO DEFENCATH
Read more
2024-04-19
CORMEDIX INC. ANNOUNCES U.S. INPATIENT COMMERCIAL AVAILABILITY OF DEFENCATH® (TAUROLIDINE AND HEPARIN)
Read more
2024-04-15
CORMEDIX INC. ANNOUNCES ABSTRACTS AT UPCOMING SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA CONFERENCE
Read more
2024-04-11
CORMEDIX INC. ANNOUNCES COMMERCIAL AGREEMENT WITH ARC DIALYSIS, LLC
Read more
2024-04-08
CORMEDIX INC. TO PRESENT AT THE NEEDHAM ANNUAL HEALTHCARE CONFERENCE
Read more
2024-03-27
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2024-03-12
CORMEDIX INC. TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MARCH 12, 2024
Read more
2024-03-06
CORMEDIX INC. ANNOUNCES COMMERCIAL AND REIMBURSEMENT UPDATES
Read more
2024-01-30
CORMEDIX INC. ANNOUNCES COMMERCIAL AND OPERATIONAL UPDATES
Read more
2024-01-08
CORMEDIX INC. ANNOUNCES APPPOINTMENT OF CHIEF LEGAL OFFICER
Read more
2023-12-15
CORMEDIX INC. ANNOUNCES PARTNERSHIP WITH THE LEAPFROG GROUP
Read more
2023-12-04
CORMEDIX INC. ANNOUNCES FDA APPROVAL OF DEFENCATH® TO REDUCE THE INCIDENCE OF CATHETER-RELATED BLOODSTREAM INFECTIONS IN ADULT HEMODIALYSIS PATIENTS
Read more
2023-11-15
CORMEDIX INC. REPORTS THIRD QUARTER AND NINE MONTH 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2023-11-14
CORMEDIX INC. TO REPORT THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON NOVEMBER 14, 2023
Read more
2023-11-06
CORMEDIX INC. TO PRESENT AT THE CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE
Read more
2023-09-26
CORMEDIX INC. TO PRESENT AT THE H.C. WAINWRIGHT ANNUAL GLOBAL INVESTMENT CONFERENCE
Read more
2023-09-06
CORMEDIX INC. ANNOUNCES ISSUANCE OF U.S. PATENT COVERING LEAD PRODUCT DEFENCATH
Read more
2023-08-30
CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2023-08-08
CORMEDIX INC. TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 8, 2023
Read more
2023-07-27
CORMEDIX INC. ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS
Read more
2023-06-28
CORMEDIX INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS
Read more
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE OF RESUBMISSION OF NEW DRUG APPLICATION FOR DEFENCATH
Read more
2023-06-21
CORMEDIX INC. ANNOUNCES STRATEGIC INITIATIVE WITH BOSTON MEDICAL CENTER TO REDUCE HEALTH DISPARITIES IN PATIENTS AT RISK FOR BLOODSTREAM INFECTIONS
Read more
2023-06-15
CORMEDIX INC. TO PRESENT AT THE JEFFERIES HEALTHCARE CONFERENCE
Read more
2023-05-30
CORMEDIX INC. ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION FOR DEFENCATH
Read more
2023-05-16
CORMEDIX INC. TO REPORT FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 15, 2023
Read more
2023-05-08
CORMEDIX INC. TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES
Read more
2023-05-03
CORMEDIX INC. ANNOUNCES NOTICE OF ALLOWANCE FOR U.S. PATENT APPLICATION COVERING LEAD PRODUCT DEFENCATH
Read more
2023-05-01
CORMEDIX INC. ANNOUNCES REGULATORY, MANUFACTURING AND REIMBURSEMENT UPDATES
Read more
2023-04-26
CORMEDIX INC. ANNOUNCES APPOINTMENT OF ROBERT A. STEWART TO ITS BOARD OF DIRECTORS
Read more
2023-04-17
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2023-03-30
CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES
Read more
2023-03-02
CORMEDIX INC. ANNOUNCES PROMOTIONS IN COMMERCIAL AND TECH OPS
Read more
2023-01-18
CORMEDIX INC. ANNOUNCES PRESENTATION AT CONFERENCE SHOWING MORTALITY RISK AND COMPLICATIONS IN PATIENTS EXPERIENCING CATHETER RELATED BLOOD STREAM INFECTIONS
Read more
2022-12-06
CORMEDIX INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2022-11-10
CORMEDIX INC. TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON NOVEMBER 10
Read more
2022-11-02
CORMEDIX INC. ANNOUNCES ABSTRACT PRESENTATION AT UPCOMING AMERICAN SOCIETY OF NEPHROLOGY CONFERENCE
Read more
2022-10-20
CORMEDIX INC. ANNOUNCES CMS REVISION TO NTAP REIMBURSEMENT OF DEFENCATH
Read more
2022-09-07
CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2022 Financial Results and Provides Business Update
Read more
2022-08-11
CORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES
Read more
2022-08-08
CORMEDIX INC. TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 11
Read more
2022-08-01
CorMedix to Participate at the JMP Securities Life Sciences Conference
Read more
2022-06-08
CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
Read more
2022-05-12
CORMEDIX INC. ANNOUNCES LEADERSHIP UPDATES AND OPERATIONAL CHANGES
Read more
CORMEDIX INC. TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 12
Read more
2022-05-03
CORMEDIX INC. ANNOUNCES SCIENTIFIC ADVISORY BOARD TO SUPPORT COMMERCIALIZATION and pipeline development
Read more
2022-04-07
CORMEDIX INC. to Present at the 21st Annual Needham Virtual Healthcare Conference
Read more
2022-04-04
CORMEDIX INC. REPORTS fourth QUARTER and full year 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2022-03-29
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH
Read more
2022-03-28
CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29
Read more
2022-03-22
CORMEDIX INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER
Read more
2022-03-17
CORMEDIX INC. ANNOUNCES RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH
Read more
2022-02-28
CORMEDIX TO PARTICIPATE IN UPCOMING JANUARY CONFERENCES
Read more
2022-01-04
CORMEDIX INC. REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2021-11-09
CorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9
Read more
2021-11-02
CORMEDIX INC. ANNOUNCES ABSTRACTS AT UPCOMING CONFERENCES SHOWING PATIENT OUTCOMES AND ECONOMIC BURDEN OF CRBSI
Read more
2021-10-20
CORMEDIX INC. ANNOUNCES EXECUTIVE LEADERSHIP CHANGES
Read more
2021-10-04
CORMEDIX INC. ANNOUNCES REGULATORY UPDATE
Read more
2021-09-07
CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2021-08-12
CorMedix Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12
Read more
2021-07-28
CorMedix Inc. Completes Sale of $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program
Read more
2021-06-10
CorMedix Inc. to Participate in Fireside Chat at the JMP Securities Life Sciences Conference
Read more
2021-06-09
CorMedix Inc. to Present at the Jefferies Virtual Healthcare Conference
Read more
2021-05-27
CorMedix Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
Read more
2021-05-13
CorMedix Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13
Read more
2021-05-05
CORMEDIX INC. TO PARTICIPATE AT THE 7th ANNUAL TRUIST SECURITIES LIFE SCIENCES SUMMIT
Read more
2021-04-28
CORMEDIX HAS MEETING WITH FDA ON DEFENCATH CATHETER LOCK SOLUTION NDA
Read more
2021-04-14
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2021-03-30
CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update on March 30
Read more
2021-03-23
CorMedix Approved to Sell $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program
Read more
2021-03-15
CorMedix Inc. to Host Regulatory Update Conference Call
Read more
2021-03-08
CORMEDIX RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH™ CATHETER LOCK SOLUTION
Read more
2021-03-01
CORMEDIX INC. TO BEGIN TRADING ON THE NASDAQ STOCK EXCHANGE
Read more
2021-01-21
CORMEDIX INC. ANNOUNCES FDA DECISION THAT ADVISORY COMMITTEE MEETING FOR NEW DRUG APPLICATION FOR DEFENCATH IS NOT NEEDED
Read more
2020-11-18
CORMEDIX INC. REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2020-11-05
CorMedix Appoints Greg Duncan to its Board of Directors
Read more
2020-11-02
CorMedix Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 5
Read more
2020-10-29
CorMedix to Participate in BIO Investor Forum Digital
Read more
2020-10-08
Cormedix Appoints Paulo Costa to its Board of Directors
Read more
2020-09-17
CorMedix Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Read more
2020-09-09
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE FOR FILING AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR DEFENCATH
Read more
2020-08-31
CORMEDIX INC. REPORTS SECOND QUARTER AND SIX MONTH 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2020-08-10
CorMedix Inc. to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 10
Read more
2020-08-04
CorMedix Announces Pricing of $20M Public Offering of Common Stock
Read more
2020-07-28
CorMedix Announces Proposed Public Offering of Common Stock
Read more
2020-07-27
CORMEDIX INC. REPORTS SUBMISSION OF DEFENCATH™ NEW DRUG APPLICATION
Read more
2020-07-08
CORMEDIX INC. REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2020-05-11
CORMEDIX INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER
Read more
CorMedix Hosting KOL Call on Antimicrobial Resistance, Catheter-Related Bloodstream Infections (CRBSIs), and the Potential for Neutrolin®
Read more
2020-05-06
CorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program
Read more
2020-04-22
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2020-03-17
CorMedix Inc. to Report Fourth Quarter 2019 Financial Results and Provide a Corporate Update on March 16
Read more
2020-03-06
CORMEDIX APPROVED TO SELL $5.5 MILLION OF NOL TAX BENEFITS THROUGH THE NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM
Read more
2020-02-03
CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin® New Drug Application
Read more
CORMEDIX INC. REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2019-11-14
CorMedix Inc. Announces a Change to its Senior Leadership
Read more
2019-11-06
CORMEDIX COMPLETES SUCCESSFUL CMC INTERACTION WITH THE FDA
Read more
2019-10-21
CORMEDIX INC. ANNOUNCES EXERCISES OF OUTSTANDING WARRANTS
Read more
2019-09-30
CORMEDIX INC. ANNOUNCES EXCHANGE AGREEMENT WITH ITS LARGEST INVESTOR
Read more
2019-08-15
CORMEDIX PRESENTS AT FDA PUBLIC MEETING ON THE LIMITED POPULATION PATHWAY FOR ANTIBACTERIAL AND ANTIFUNGAL DRUGS
Read more
2019-07-17
CORMEDIX RECEIVES ENCOURAGING FDA FEEDBACK ON NEUTROLIN® LOCK-IT-100 DATA
Read more
2019-07-09
CORMEDIX ANNOUNCES PUBLICATION OF TAUROLIDINE PRE-CLINICAL ONCOLOGY DATA IN “INVESTIGATIONAL NEW DRUGS” JOURNAL
Read more
2019-07-08
CorMedix Inc. Set to Join the Russell 2000® Index
Read more
2019-06-26
CorMedix Inc. to Ring NYSE Closing Bell on Monday, June 10
Read more
2019-06-10
CORMEDIX INC. REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2019-05-14
CORMEDIX ANNOUNCES PRESENTATION OF LOCK-IT-100 STUDY RESULTS AT NATIONAL KIDNEY FOUNDATION SPRING 2019 MEETING
Read more
2019-05-10
CORMEDIX ANNOUNCES ONLINE PRE-CLINICAL ABSTRACT AT THE UPCOMING ANNUAL MEETING OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY
Read more
2019-04-22
CORMEDIX COMPLETES SALE OF $5.4 MILLION OF NOL TAX BENEFITS THROUGH NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM
Read more
2019-04-17
CORMEDIX NOTIFIED OF COMPLIANCE WITH NYSE AMERICAN LISTING REQUIREMENTS
Read more
2019-04-11
CORMEDIX CONFIRMS PREVIOUSLY ANNOUNCED ONE-FOR-FIVE REVERSE STOCK SPLIT
Read more
2019-03-25
CORMEDIX INC. ANNOUNCES APPOINTMENT OF PHOEBE MOUNTS AS EXECUTIVE VICE PRESIDENT AND GENERAL COUNSEL
Read more
2019-03-21
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS, ANNOUNCES REVERSE STOCK SPLIT AND PROVIDES BUSINESS UPDATE
Read more
2019-03-14
CORMEDIX INC. APPOINTS ALAN W. DUNTON, M.D. TO BOARD OF DIRECTORS
Read more
2019-03-04
CORMEDIX INC. ANNOUNCES FDA MEETING UPDATE
Read more
2019-02-14
CORMEDIX INC. ANNOUNCES TOPLINE ANALYSIS OF THE FULL DATA SET OF PHASE 3 LOCK-IT-100 STUDY REINFORCES THE INTERIM RESULTS
Read more
2019-01-30
CORMEDIX INC. ANNOUNCES HIGHLY STATISTICALLY SIGNIFICANT TOPLINE RESULTS FOR NEUTROLIN® FROM THE INTERIM ANALYSIS OF THE PHASE 3 LOCK-IT-100 STUDY
Read more
2019-01-17
CORMEDIX INC. ANNOUNCES RESIGNATION OF MEMBER OF ITS BOARD OF DIRECTORS
Read more
CORMEDIX ANNOUNCES CLOSING OF $7.5 MILLION SENIOR SECURED CONVERTIBLE DEBT FINANCING
Read more
2019-01-07
CORMEDIX RECEIVES APPROVAL TO SELL $5.4 MILLION OF NOL TAX BENEFITS THROUGH THE NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM
Read more
2018-12-10
CORMEDIX INC. REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call today at 4:30 p.m. Eastern Time
Read more
2018-11-14
CORMEDIX INC. CLARIFIES THAT NO NEW SHARES ARE BEING ISSUED IN CONNECTION WITH ITS RECENTLY FILED FORM S-3 REGISTRATION STATEMENT
Read more
2018-10-18
CorMedix Announces NYSE American Acceptance of Plan to Regain Listing Compliance
Read more
2018-08-31
CORMEDIX INC. TO PRESENT AT THE 20TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE
Read more
2018-08-30
CORMEDIX INC. REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2018-08-14
CORMEDIX INC. ANNOUNCES POSITIVE RESULTS OF ITS NEUTROLIN® PHASE 3 LOCK-IT-100 STUDY BASED ON RECOMMENDATION BY INDEPENDENT DATA SAFETY MONITORING BOARD
Read more
2018-07-25
CORMEDIX INC. COMPLETES REVIEW AND SOURCE VERIFICATION OF PHASE 3 LOCK-IT 100 DATA FOR NEUTROLIN®
Read more
2018-06-20
CORMEDIX INC. RECEIVES A CONTINUED LISTING STANDARD NOTICE FROM THE NYSE AMERICAN
Read more
2018-06-19
CORMEDIX INC. REPORTS PROGRESS ON LOCK-IT 100 DATA REVIEW AND APPOINTS PAUL CHEW AS CONSULTANT ADVISOR CMO
Read more
2018-05-29
CORMEDIX INC. REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2018-05-15
CorMedix Inc. to Report First Quarter 2018 Financial Results on Tuesday, May 15
Read more
2018-05-09
CorMedix Revises Timeline and Announces Changes to Lock-It-100 Study Management
Read more
2018-04-27
CORMEDIX INC. REPORTS Fourth QUARTER and Full-year 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Read more
2018-03-19
CorMedix Inc. Provides Update on its Financing Plans in Connection with its Ongoing LOCK-IT 100 Clinical Study
Read more
2018-02-27
CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma
Read more
2018-02-26
CorMedix Inc. Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin® for Interim Efficacy Analysis
Read more
2018-02-20